Risankizumab - AbbVie/Boehringer Ingelheim

Drug Profile

Risankizumab - AbbVie/Boehringer Ingelheim

Alternative Names: ABBV 066; BI-655066

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Crohn's disease
  • Phase II/III Ulcerative colitis
  • Phase II Ankylosing spondylitis; Asthma
  • Phase I Psoriasis

Most Recent Events

  • 19 Jul 2018 Phase-III clinical trials in Plaque psoriasis in Russia (SC) (NCT03518047)
  • 06 Jul 2018 AbbVie completes a phase III trial in Plaque psoriasis in Germany (SC) (NCT03255382)
  • 10 Jun 2018 Efficacy and adverse events data in Psoriatic arthritis presented at 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top